1.1 Key Findings

1.2 Analysis Framework: Frost & Sullivan’s Core Value

1.3 Research Methodology

2.1 Global Non-opioid Market

2.2 NSAIDs Continue to be Important for Pain Treatment

2.3 Types of Non-opioid Pharmaceuticals

2.4 Categories of Non-opioids in Development for Pain Management

2.4.1 Recently Approved Monoclonal Antibodies for Pain Management

2.5 Emerging Non-opioid Analgesics

2.6 Advanced Academic Researches in Pain Therapy

2.6 Advanced Academic Researches in Pain Therapy (continued)

3.1 Innovation Radar of Emerging Technologies

3.2 Summary of the Scoring Methodology

3.2.1 QBioMed

3.2.1 QBioMed (continued)

3.2.2 Centrexion Therapeutics

3.2.2 Centrexion Therapeutics (continued)

3.2.3 Concentric Analgesics

3.2.3 Concentric Analgesics (continued)

3.2.4 Xenon Pharmaceuticals

3.2.4 Xenon Pharmaceuticals (continued)

3.2.5 KinetaBio

3.2.5 KinetaBio (continued)

3.2.6 Navega Therapeutics

3.2.6 Navega Therapeutics (continued)

3.2.7 Tetra Biopharma

3.2.7 Tetra Biopharma (continued)

3.2.8 Vapogenix

3.2.8 Vapogenix (continued)

4.1 Pain Therapy Innovations Roadmap

4.2 Growth Opportunity 1: R&D Investment

4.3 Growth Opportunity 2: Technology Convergence

4.4 Conclusion

5.1 IP Overview in Non-opioid Pharmaceuticals

5.2 Leading Pharmaceutical Patent Holders

5.3 Patent Scenario

5.3Patent Scenario

6.1 List of Non-opioids in the Market

6.2 Key Industry Contacts

6.2 Key Industry Contacts (continued)

Legal Disclaimer